Research use only. Read more

Metabolic / GLP-1

Retatrutide

A triple agonist of GIP, GLP-1, and glucagon receptors currently in late-phase research for obesity and metabolic indications.

Research consideration: Phase 3 research-stage molecule. 24 mg, 40 mg and 60 mg variants are typically pre-mixed cartridge pens.

Quick facts

Molecular weight

4,731 Da

Half-life

144 h

Frequency

weekly

Admins / wk

1

Routes

SubQ

Typical dose

500 mcg–12.0 mg

Mechanism & positioning

A triple agonist of GIP, GLP-1, and glucagon receptors currently in late-phase research for obesity and metabolic indications.

Researched for: triple GIP/GLP-1/glucagon agonism, adipose mobilisation.

Reconstitution defaults

Default vial

10 mg

BAC water

2 mL

Concentration

5000 mcg/mL

Doses per vial

~20

Other stocked vial sizes: 24, 40, 60 mg.

Calculate with this peptide

Documented pairwise interactions

  • avoid

    Retatrutide + Semaglutide

    Overlapping GLP-1 receptor agonism; combined effects unpredictable in current literature.

  • avoid

    Retatrutide + Tirzepatide

    Both are multi-receptor incretin agonists; concurrent use exceeds any published research protocol.

References

  • Jastreboff AM et al., NEJM, 2023.

Related peptides in the Metabolic / GLP-1 class

Frequently asked questions about Retatrutide

What is the typical research dose range for Retatrutide?
Retatrutide is most commonly investigated at 500 mcg–12.0 mg per administration, weekly. Note: weekly titration. These values reflect documented research-stage protocols and are not medical recommendations.
What is the half-life of Retatrutide?
Retatrutide has an approximate plasma half-life of 144 hours. Practical steady state is reached after roughly five half-lives — about 30 days under continuous administration.
How is Retatrutide administered in research protocols?
Published research uses subq administration. Typical reconstitution is 10 mg vial in 2 mL of bacteriostatic water, producing a concentration of 5000 mcg/mL.
What vial sizes are commonly available for Retatrutide?
Common stocked vial sizes are 10 mg, 24 mg, 40 mg, 60 mg. The 10 mg vial is the most-used default in published protocols.
Anything important to know about Retatrutide before designing a protocol?
Phase 3 research-stage molecule. 24 mg, 40 mg and 60 mg variants are typically pre-mixed cartridge pens.